October has been and gone, and we're approaching that festive season already. Let' take a look back at our bloggers ...
Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.
The scene was set for the first game of the 2024 Pacific Championships on Friday night with a powerful Sipi Tau from the Tongan team. Veteran hooker Siliva Havili led the way for Tonga as the ...
Charlie Hall is Polygon’s tabletop editor. In 10-plus years as a journalist & photographer, he has covered simulation, strategy, and spacefaring games, as well as public policy. Kitbashing is ...
TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...
UCB will advance its anti-tau antibody for Alzheimer’s disease solo after Roche and Genentech walked away from the asset known as bepranemab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback